Beige J, Kreutz R, Rothermund L
Fachbereich Nephrologie und KfH Nierenzentrum, Klinikum St. Georg gGmbH.
Dtsch Med Wochenschr. 2007 Nov;132(48):2569-78. doi: 10.1055/s-2007-993100.
The main pathomechanism of acute renal failure (ARF) is acute tubular necrosis (ATN) due to reduced perfusion of renal cortex resulting in ischemic injury. ATN has the potential for complete restitution. However, acute renal failure is often complicated by pre-existing renal disease, ongoing toxic injury or non-recovery of systemic circulation. From a clinical point of view, the reason of tubular injury may be based on pre-renal causes, glomerular- and/or interstitial disorders or obstructive nephropathy. Therapy must be specifically targeted on the underlying causes to overcome ARF. If kidney function is not reconstituted in an appropriate time period, renal replacement therapy has to be initiated. Recent evidence for improved patient survival supports an augmented dialysis dose to achieve a maximum of metabolic, volume and electrolyte control. To reach these goals, daily intermittent or continuous forms of hemodialysis or hemofiltration are appropriate measures.
急性肾衰竭(ARF)的主要发病机制是急性肾小管坏死(ATN),这是由于肾皮质灌注减少导致缺血性损伤所致。急性肾小管坏死有完全恢复的可能。然而,急性肾衰竭常并发既往存在的肾脏疾病、持续的毒性损伤或全身循环未恢复。从临床角度看,肾小管损伤的原因可能基于肾前性病因、肾小球和/或间质疾病或梗阻性肾病。治疗必须针对潜在病因以克服急性肾衰竭。如果肾功能在适当时间内未恢复,则必须开始肾脏替代治疗。近期关于改善患者生存率的证据支持增加透析剂量以实现最大程度的代谢、容量和电解质控制。为实现这些目标,每日间歇性或连续性血液透析或血液滤过是合适的措施。